• Sheraton New York Times Square Hotel (map)
  • 811 7th Avenue
  • New York, NY, 10019
  • United States

Session Chairs:  Ira Mellman, Genentech, Inc., South San Francisco, CA, and Drew M. Pardoll, Johns Hopkins Medicine, Baltimore, MD

8:00 a.m.  Ira Mellman, Genentech, Inc., South San Francisco, CA
Mechanism-based combination strategies in cancer immunotherapy

8;40 a.m.  Drew M. Pardoll, Johns Hopkins Medicine, Baltimore, MD
How much cancer can we cure with the immune system?

9:10 a.m.  Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX
Rational combinations of targeted and immunotherapies

9:40 a.m.  Refreshment Break

10:10 a.m.  Romina Goldszmid, National Cancer Institute, NIH, Bethesda, MD
Is the right flavor of inflammation the key to successful therapy?

10:40 a.m.  David A. Reardon, Dana-Farber Cancer Institute, Boston, MA
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naive patients with recurrent GBM

11:10 a.m.  Mary Philip, Memorial Sloan Kettering Cancer Center, New York, NY
Identifying the epigenetic code of tumor-specific CD8 T cell dysfunction and therapeutic reprogramming*

11:25 a.m.  Martin Oft, ARMO, Palo Alto, CA
Anti-tumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1*

* Proffered presentation